Abingdon Health PLC Notice of Results (6893P)
October 11 2023 - 1:00AM
UK Regulatory
TIDMABDX
RNS Number : 6893P
Abingdon Health PLC
11 October 2023
Abingdon Health plc
("Abingdon Health" or "the Company")
Notice of Results
Investor presentation
York, U.K. 11 October 2023: Abingdon Health plc (AIM: ABDX), a
leading international lateral flow contract development and
manufacturing organisation (CDMO), announces that its final results
for the year ended 30 June 2023 will be issued on Tuesday 17
October 2023.
Investor presentation
The Company will provide a live presentation relating to the
final results via the Investor Meet Company platform on Tuesday 24
October 2023 at 5.00pm BST.
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your
Investor Meet Company dashboard up until 9am the day before the
meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add
to meet Abingdon Health plc via:
https://www.investormeetcompany.com/abingdon-health-plc/register-investor
Investors who already follow Abingdon Health plc on the Investor
Meet Company platform will automatically be invited.
Enquiries
Abingdon Health plc www.abingdonhealth.com/investors/
Chris Yates, Chief Executive Officer Via Walbrook PR
Melanie Ross, Chief Financial Officer
Chris Hand, Non-Executive Chairman
Singer Capital Markets (Sole Broker and Tel: +44 (0)20 7496 3000
Nominated Adviser)
Peter Steel, Alex Bond (Corporate Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
Paul McManus / Phillip Marriage Mob: +44 (0)7980 541 893 / +44 (0)7867
Alice Woodings 984 082
+44 (0)7407 804 654
About Abingdon Health plc
Abingdon Health is a leading lateral flow contract development
and manufacturing organisation ("CDMO") offering its services to an
international customer base across industry sectors that include
clinical, animal health, plant health, and environmental testing.
Abingdon Health has the internal capabilities to take projects from
initial concept through to routine and large-scale manufacturing;
from "idea to commercial success."
The Company's CDMO division offers product development,
regulatory support, technology transfer and manufacturing services
for customers looking to develop new assays or transfer existing
laboratory-based assays to a lateral flow format. Abingdon Health
aims to support the increase in need for rapid results across many
industries and locations and produces lateral flow tests in areas
such as infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access
to results allows for rapid decision making, targeted intervention
and can support better outcomes.
Abingdon Health's Abingdon Simply Test (R) range of self-tests
is an ecommerce platform that offers a range of self-tests to
empowers consumers to manage their own health and wellbeing. The
Abingdon Simply Test (R) ecommerce site offers consumers a range of
information to support them in making informed decisions on the
tests available. In addition, the site provides Abingdon's contract
services customers with a potential route to market for self-tests.
The Abingdon Simply Test (R) range is also sold through
international distributors and through other channels in the UK and
Ireland such as pharmacy chains.
Founded in 2008, Abingdon Health is headquartered in York,
England.
For more information visit: www.abingdonhealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORBLBDGRBBDGXG
(END) Dow Jones Newswires
October 11, 2023 02:00 ET (06:00 GMT)
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Apr 2024 to May 2024
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From May 2023 to May 2024